German policy-making has undertaken important steps to strengthen clinical research in Germany. However, the industry continues to complain about disadvantages in the competition with other countries. Although the number of clinical studies has been rising during the last years, this increase has been significantly bigger in some competing countries. In the long run this could impact on employment and supply of patients with innovative pharmaceuticals, as new products are introduced preferredly in those countries in which the clinical trials had taken place.

In addition, the traditional procedures of clinical research are questioned by new, mostly biotechnological therapy methods, e.g. gene or cell therapies or monoclonal anti-bodies, or by nano medicine, for which the existing evidence is still relatively weak and which therefore can hold particular risks for patients and study participants. For these new procedures, scientific development forges ahead at quick pace, so that the framework conditions in particular for the protection of the participants in clinical trials have to be re-assessed and adopted to new challenges frequently, but without hampering the carrying-out of clinical studies in Germany too much.

Aims of the project were the description and assessment of the various conditions of Germany as research location for clinical trials and an in-depth analysis for the area of biomedical innovations.

Duration: May 2007 – June 2009

Funding: Office for Technology Assessment at the German Federal Parliament (TAB)

Project lead: Bernhard Bührlen at Fraunhofer ISI

Weblink: Website of the study at TAB

Cookies user preferences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Tools used to give you more features when navigating on the website, this can include social sharing.
These cookies are needed to make the website work correctly. You can not disable them.
Set of techniques which have for object the commercial strategy and in particular the market study.